Ipilimumab immune checkpoint inhibition
systematic review meta-analysis network meta-analysis
 

MDX-010 - MDX010 - DX 010 - Yervoy - MDX-CTLA-4      

Select             pdf
Filter

  • Group by...
Trial Studied trt Control trt patientstagsROB Trial resultdeath (overall survival) progression or death (progression free survival PFS)

lung cancer (metastatic)  

Reck, 2016      NCTipilimumab + chemotherapyplacebo + chemotherapySCLCLow risk of bias -
Govindan, 2017      NCTipilimumab + chemotherapyplacebo + chemotherapy1LLow risk of bias negative-9%
phase 2 (phased ipilimumab), 2012     ipilimumab + chemotherapyplacebo + chemotherapyLow risk of bias -

melanoma  

Robert, 2011      NCTipilimumab + dacarbazinedacarbazine1L 1st line Low risk of bias conclusive-28%
Hodi (ipi + gp100), 2010      NCTipi + gp100gp1002L 2nd line Risk of bias suggesting-31%
Hodi (ipi alone), 2010      NCTipilimumab 3 mg/kggp1002L 2nd line Risk of bias suggesting-36%
EORTC 18071 (Eggermont), 2015        NCTipilimumabplaceboadjuvant adjuvant Low risk of bias conclusive -28%-24%



- About - Browse pathology | treatment - Site map - Credits Made with in Lyon - Contact us - Privacy policy - Licence Creative Commons